Poor prognosis acute myelogenous leukemia 2 - Biological and molecular biological characteristics and treatment outcome

Leukemia Research

Volumn 24, Issue 9, 2000, Pages 777-789

  Li, Biarou ^a   Yang, Jie ^a   Tao, Ming ^a   Nayini, Jaya ^a   Horvath, Erzsebet ^a   Chopra, Harpareet ^a   Meyer, Peterm ^a   Venugopal, Paramesaran ^a   Preisler, Harvey D ^a  

^a RUSH CANCER INSTITUTE   (United States)

Author keywords

Amifostine; AML; Cytokines; Remission induction

Indexed keywords

AMIFOSTINE; CYTOKINE; INTERLEUKIN 6; TELOMERASE;

ARTICLE; BONE MARROW CELL; CANCER REGRESSION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

AMIFOSTINE; BASE SEQUENCE; DNA PRIMERS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; PROGNOSIS; TREATMENT OUTCOME;

EID: 0034284015     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00035-7     Document Type: Article

References (46)

1. Preisler H.D., Raza A., Barcos M., Azarnia N., Larson R., Browman G., et al. High dose cytosine arabinoside as the initial treatment of poor risk patients with acute nonlymphocytic leukemia: A Leukemia Intergroup Study. J. Clin. Oncol. 5:1987;75-82.
2. Gajewski J.L., Ho W.G., Nimer S.D., Hirji K.F., Gakelman L., Jacobs A.D., et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemia syndrome. J. Clin. Oncol. 7:1989;1637-1645.
3. Preisler H.D., Larson R.A., Raza A., Browman G., Goldberg J., Vogler R., et al. The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukemia: response to treatment and treatment failure. Br. J. Haematol. 79:1991;390-397.
4. 1 transcript levels as an indication of resistant disease in acute nonlymphocytic leukemia. Br. J. Haematol. 75:1990;340-345.
5. Preisler H.D., Venugopal P. Regrowth resistance in leukemia and lymphoma: The need for a new system to classify treatment failure and for new approaches to treatment. Leuk. Res. 18:(3):1994;149-160.
6. Preisler H.D., Raza A., Bonomi P., Taylor S., LaFollette S., Leslie W., et al. Regrowth resistance as a likely significant contributor to treatment failure in drug sensitive neoplastic disease. Cancer Invest. 15:(4):1997;358-368.
7. Preisler H.D., Raza A., Larson A., Goldberg J., Tricot G., Carey M., et al. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia. Leuk. Res. 15:(9):1992;773-780.
8. Preisler HD, Venugopal P, Gregory SA, Hsu W-T, Loew J, Adler S, et al. Poor prognosis acute myelogenous leukemia: I - response to treatment with high dose cytarabine/mitoxantrone/ amifostine, Leuk Res 1999 (submitted).
9. Preisler HD, Li B, Yang J, Huang RW, Devemy E, Venugopal P, et al. Suppression of telomerase activity cytokine mRNA level in acute myelogenous leukemia cells in vivo in patients by amifostine and IL-4, Clin Cancer Res 1999 (in press).
10. Anderlini P., Luna M., Kantarjian H.M., O'Brien S., Pierce S., Keating M.J., et al. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 10:1996;600.
11. Preisler H.D. Treatment failure in AML. Blood cells. 8:1982;585-602.
12. Radich J.P., Kopecky K.J., Appelbaum F. N-ras mutations in acute myelogenous leukemia: A review of the current literature and an update of the Southwest Oncology Group experience. Leuk. Lymp. 6:1992;325-334.
13. Tobal K., Pagliuca A., Bhatt B., Bailey N., Layton D.M., Muffi G.J. Mutation of the human FMS gene (M-CSF Receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia. 4:(7):1990;486-489.
14. Imamura J., Miyoshi I., Koeffler H.P. p53 in hematologic malignancies. Blood. 84:(8):1994;2412-2421.
15. Morrison S.J., Prowse K.R., Ho P., Weissman I.L. Telomerase activity in hematopoietic cells is associated with self-renewal potential. Immunity. 5:1996;207-216.
16. Li B, Yang J, Andrews C, Chen Y-X, Toofanfard P, Huang R-W, et al. Telomerase activity in preleukemia and acute myelogenous leukemia, Leuk Lymp, 1999 (in press).
17. INK4B gene in myelodysplastic syndromes. Blood. 90:(4):1997;1403-1409.
18. INK4B gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 91:(8):1998;2985-2990.
19. Gao X.Z., Bi S., Chopra H., Devemy E., Venugopal P., Li B., et al. Cytokine gene activity AML cells in vivo in patients. Leuk. Res. 22:1998;429-438.
20. Bradbury D., Rogers S., Reilly I.A.G., Kozlowski R., Rossell N.H. Role of autocrine and paracrine production of granitlocyte-macrophage colony-stimulation factor and interleukin-1β in the autonomous growth of acute myeloblastic leukaemia cells: studies using purified CD34-positive cells. Leukemia. 6:(6):1992;562-568.
21. Lowenberg B., Touw I.P. Hematopoietic growth factors and their receptors in acute leukemia. Blood. 81:(2):1993;281-292.
22. Raza A., Maheshwari Y., Preisler H.D. Differences in cell cycle characteristics amongst patients with acute nonlymphocytic leukemia. Blood. 69:(6):1987;1647-1653.
23. Kotelnikov V., Cass L., Coon J.S., Spaulding D., Preisler H.D. Accuracy of histone H3 messenger RNA in situ hybridization for the assessment of cell proliferation in human tissues. Clin. Cancer Res. 3:1997;669-675.
24. Raza A., Gezer S., Mundle S., Gao X.-Z., Alvi S., Borok R., et al. Apoptosis in bone marrow biopsies involving stromal and hematopoictic cells in 50 patients with myelodysplastic syndromes. Blood. 86:(1):1995;268-276.
25. Stratton M.R., Fisher C., Gusterson B.A., Copper C.S. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 1549:(22):1989;6324-6327.
26. Springall F., O'Mara S., Shounan Y., Todd A., Ford D., Iland H. c-fms point mutations in acute myeloid leukemia: fact or fiction? Leukemia. 7:(7):1993;978-985.
27. Taylor C., McGlynn H., Carter G., Baker A.H., Warren N., Ridge S.A., et al. RAS and FMS mutations following cytotoxic therapy for childhood acute lymphoblastic leukaemia. Leukemia. 9:(3):1995;466-470.
28. Zaheer H.A., Bagnara M., Gibson F.M., Robinson G., Rutherford T.R. Persistence of an activation N-RAS oncogene mutation in clonogenic progenitor cells from an acute myeloid leukaemia patient in remission. Br. J. Haematol. 86:(2):1994;298-330.
29. Li B, Horvath E, Chen H, Yang J, Larson A, Chen Y, et al. Study on unequal template-oligonucleotide duplexes by FMS site-directed mutation model for quantitative assay, Mol. Cell Biol. 1999 (submitted).
30. Marchetti A., Buttitta F., Merlo G., Diella F., Pellegrini S., Pepe S., et al. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res. 15:1993;2846-2851.
31. Tao M, Li B, Nayini J, Andrews CB, Huang R-W, Yang J, et al. SCF, IL1α, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. Cytokine 1999 (in press).
32. Yousuf N, Masterson M, Hulette B, Lampkin B, Raza A, Preisler HD. C-myc proto-oncogene expression in childhood acute lymphoblastic leukemia (ALL), Blood 1991;78(10):447a, abstr no. 1778.
33. Preisler H.D., Raza A. Current problems in the treatment of acute myelocytic leukemia (AML) and some possible solutions. Leukemia. 6:(2):1992;81-84.
34. Devemy E, Li B, Tao M, Yang J, Horvath E, Chopra H, et al. Poor prognosis acute leukemia: 3 - biological and molecular biological changes during remission induction therapy, Blood 1999 (submitted).
35. Preisler HD, Gao X-Z, Chopra H, Devemy E, Venugopal P, Bi S. Control of leukemia proliferation in vivo in patients: in vivo cytokine production. Acute Leukemias VII Symposium. In: Acute Leukemias VII, Experimental Approaches and Novel Therapies. Hiddemann W, Buchner T, Wormann B, Ritter J, Creutzig U, Keating M, et al., editors. Berlin, Heidlberg: Spinger Verlag, 1998 pp. 307-316.
36. Rowe J.M., Liesveld J.L. Hematopoietic growth factors in acute leukemia. Leukemia. 11:1997;328-341.
37. Paper in preparation
38. Bi S, Gao X, Devemy E, Chopra H, Venugopal P, Preisler HD. Cytokine production by in vitro processed and unprocessed hematopoietic cells, Cytokine 1998 (in press).
39. INK4B gene methylation and expression in MDS and AML, Leuk Res 1999 (submitted).
40. Preisler H.D., Azarnia N., Raza A., Grunwald H., Vogler R., Browman G., et al. Relationship between the percent of marrow cells in S phase and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Br. J. Haemotol. 56:1984;399-407.
41. Fourth International Workshop in Leukemia. A prospective study of acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1984;11:249.
42. De Melo M.B., Lorang-Metze I., Lima C.S.P., Saad S.T.O., Costa F.F. N-ras gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis. Leuk. Lymphoma. 24:1997;309-317.
43. Neubauer A., Dodge R.K., George S.L., Davey F.R., Silver R.T., Schiffer C.A., et al. Prognostic importance of mutations in the ras proto-oncogenes in De Novo acute myeloid leukemia. Blood. 83:(6):1994;1603-1611.
44. Preisler HD, Yang J, Li B, Chopra HK, Venugopal P, Devemy E, et al. Reduction of telomerase activity, cytokine production and proliferative rate of AML cells in vivo in patients by the administration of amifostine or IL-4, Proc Am Soc Clin Oncol 1998;17:5a (abstr no. 17).
45. Preisler HD, Kauffman S. A proposal regarding the mechanism which underlies lineage choice during hematopoietic differentiation, Leuk Res 1999 (in press).
46. Preisler H.D. Fitness landscapes and the myeloid leukemia. Leuk. Res. 23:1999;167-176.